Gastrografin in Postoperative Ileus (GAP)
After abdominal surgery there is a period of unavoidable dysfunction of the gut. During this time patients are often unable to eat and drink, and do not pass any flatus or stool. Though this resolves within a few days for most, there are a significant number (around 30%) who go on to have a prolonged period of this dysfunction known clinically as postoperative ileus. It has been clearly shown that this group of patients have worse health outcomes and spend a longer time in hospital.
The aim of this study is to trial a drug - gastrografin - in the management of prolonged postoperative ileus. Gastrografin is safe, economical, readily available, and has been used with great success in the similar condition of bowel obstruction. It is predicted that gastrografin will shorten the duration of a prolonged postoperative ileus, thus affording affected patients a better outcome from surgery.
|Prolonged Postoperative Ileus||Drug: Gastrografin Drug: Placebo||Phase 2 Phase 3|
|Official Title:||Randomised Double-blind Placebo-controlled Trial of Gastrografin in the Therapeutic Management of Prolonged Postoperative Ileus Following Elective Surgery.|
- Time from diagnosis (and administration of study drug) to resolution of prolonged postoperative ileus.
- Length of hospital stay (days) [ Time Frame: Days ]
|Study Start Date:||September 2012|
|Study Completion Date:||July 2014|
|Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
|Experimental: Gastrografin||Drug: Gastrografin|
|Placebo Comparator: Placebo||Drug: Placebo|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01648972
|Auckland City Hospital|
|Auckland, AKL, New Zealand, 1010|